EMS's hospital unit supplying medicines and solutions to hospitals and institutional healthcare buyers, reinforced by a 2026 injectables acquisition.
EMS Hospitalar supplies medicines and healthcare solutions to hospitals, clinics and institutional procurement channels. The dedicated division was created to serve this non-retail segment, with an emphasis on efficiency and safety in treatments.
In 2026 EMS reinforced the unit by acquiring Fresenius Kabi Brazil's injectables portfolio, related research and development, and the Anápolis manufacturing plant in Goiás.
Eurofarma
Eurofarma Oncologia
eurofarma.com.br
Fresenius Kabi
Fresenius Kabi Brasil Biopharma
fresenius-kabi.com
Libbs Farmaceutica
Oncológicos
libbs.com.br
| Attribute | EMS — Hospital & Institutional Medicines | Eurofarma Oncologia | Fresenius Kabi Brasil Biopharma | Oncológicos | |
|---|---|---|---|---|---|
| Provider | | | | | |
| Founded | 1964 | 1972 | — | 1958 | |
| Sells To | Consumers, Healthcare Providers, Hospitals | Consumers | — | Consumers, Enterprise | |
| Pricing Model | B2B, Product Sales | Recurring, Software, Transactional | — | Recurring, Software | |
| Ownership | Family-owned, Private | Public | — | Private |
Provider
Founded 1964
Sells To Consumers, Healthcare Providers, Hospitals
Pricing Model B2B, Product Sales
Ownership Family-owned, Private
Provider
Founded 1972
Sells To Consumers
Pricing Model Recurring, Software, Transactional
Ownership Public
Provider
Founded —
Sells To —
Pricing Model —
Ownership —
Provider
Founded 1958
Sells To Consumers, Enterprise
Pricing Model Recurring, Software
Ownership Private
Eurofarma's Hospitalar unit supplying hospital medicines and large-volume parenteral solutions, including anesthetics, to Brazilian hospitals.
Blau FarmacêuticaBlau Farmacêutica's institutional line of hospital injectables and injectable anesthetics, serving hospitals across Brazil and the SUS system.
Sandoz pioneered biosimilars with the world's first biosimilar program in 1996 and first approval in 2006.
Cristália's biological-ingredients operation, the first Brazilian pharmaceutical plant certified by Anvisa under CBPF standards.
Portfolio of high-complexity biologic and biosimilar medicines produced and distributed by Bionovis across five medical specialties.
Cristália's oncology-ingredients operation running Latin America's first high-potency oncology API plant, opened in 2019.
AmgenAmgen oncology therapy-area portfolio spanning small molecules, T-cell engagers, and monoclonal antibodies.
Eurofarma's Hospitalar unit supplying hospital medicines and large-volume parenteral solutions, including anesthetics, to Brazilian hospitals.
Blau Farmacêutica's institutional line of hospital injectables and injectable anesthetics, serving hospitals across Brazil and the SUS system.
Blau FarmacêuticaSandoz pioneered biosimilars with the world's first biosimilar program in 1996 and first approval in 2006.
Cristália's biological-ingredients operation, the first Brazilian pharmaceutical plant certified by Anvisa under CBPF standards.
Portfolio of high-complexity biologic and biosimilar medicines produced and distributed by Bionovis across five medical specialties.
Cristália's oncology-ingredients operation running Latin America's first high-potency oncology API plant, opened in 2019.
Amgen oncology therapy-area portfolio spanning small molecules, T-cell engagers, and monoclonal antibodies.
Amgen